Skip to content
TrustList
Quan Capital cover

About Quan Capital

We are Industry Veterans

Capturing evolving healthcare trends and emerging cutting-edge innovations

We are Preferred Partners

Connecting companies with extensive network and resources globally and in China

  • Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome January 26, 2023
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome
  • Kira Pharmaceuticals Announces Clearance to Initiate Phase 2 Evaluation of KP104 in IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G) in China and Australia December 20, 2022
Kira Pharmaceuticals Announces Clearance to Initiate Phase 2 Evaluation of KP104 in IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G) in China and Australia
  • Arcellx And Kite Announce Strategic Collaboration To Co- Develop And Co-Commercialize Late-Stage Clinical CART- DdBCMA In Multiple Myeloma December 9, 2022
Arcellx And Kite Announce Strategic Collaboration To Co- Develop And Co-Commercialize Late-Stage Clinical CART- DdBCMA In Multiple Myeloma

Categories & features

Ask TrustList to introduce you to Quan Capital

TrustList reads every request before passing it on, and sends it only where the funder's stage and focus look like a fit. We do not charge for introductions, and we cannot promise a reply.

Protected by reCAPTCHA — Google Privacy Policy and Terms apply.

Reviews

Write the first review of Quan Capital

Used it? Your experience helps other buyers decide.

Write a review

Questions & answers

No questions yet. Be the first to ask about Quan Capital.

Quan Capital alternatives

Similar listings buyers compare against this one.